Associate Professor Thomas Weickert

Tabs

Main

University role:

Associate Professor

Phone:

02 9399 1730

Email:

t.weickert@unsw.edu.au

Research Interests:
Schizophrenia is a debilitating disease characterized by cognitive impairment that can be related to general or regionally specific brain dysfunction and can have genetic contributions. Our Cognitive Neuronal Systems Unit of the Schizophrenia Research Laboratory at NeuRA uses functional brain imaging (fMRI), cognitive testing, and genetic analyses to define the relationships among thinking deficits, genetic influences, and brain dysfunction in people with schizophrenia. We also use findings from the Schizophrenia Molecular Neurobiology Lab at NeuRA to guide our research using brain stimulation techniques and the novel application of existing medications as add-on therapy to antipsychotics to improve thinking ability and reduce symptoms in people with schizophrenia.

Broad Research Areas:
Psychiatry, Neuroscience, Neuropsychology, Clinical Research

Qualifications:
BA, MA, MPhil, PhD

Society Memberships & Professional Activities:
Society for Neuroscience, Organization for Human Brain Mapping, Brain Sciences University of New South Wales, Schizophrenia International Research Society, Australian Neuroscience Society, Society for Mental Health Research, Schizophrenia Research Institute, Infrastructure panel, affiliated scientist, Schizophrenia Research Institute, Cognition and Connectivity Panel, Neuroscience Research Australia Research Committee, Neuroscience Research Australia Career Development Committee, Neuroscience Research Australia Healthy Volunteer Committee, Australian Schizophrenia Research Bank Associate Investigator, Schizophrenia International Research Society Publications Committee, Schizophrenia International Research Society Program Committee

Specific Research Keywords:
Schizophrenia, Psychology, Cognition, fMRI, Clinical Research

Qualifications:

Kean University of New Jersey BA Biology

Hunter College of the City University of New York MA Psychology

City University of New York Graduate School MPhil Psychology

City University of New York Graduate School PhD Psychology

Grants:

2014-2017 Stanley Medical Research Institute, USA. Canakinumab adjunctive treatment trial to reduce symptoms and improve cognition in patients with schizophrenia displaying elevated peripheral IL-1beta. (Weickert TW, Weickert CS, Catts SV, Lenroot R, Galletly C, Wakefield D, Lloyd A). USD 361,132.

Awards:

2016 NARSAD Independent Investigator Award (Brain and Behavior Research Foundation, USA)

Research

Research activities:

Canakinumab Add-on Treatment in Schizophrenia (CATS)

Psychotic symptoms, cognitive impairment, and treatment response are variable in schizophrenia, highlighting heterogeneity in the etiology and presentation of the illness and a critical need for novel treatment approaches targeting subgroups with shared features. One recently recognized subgroup of people with schizophrenia pertains to those patients with neuroinflammation. Cytokines are involved in immunological responses and one of the leading theories regarding the etiology of schizophrenia based on epidemiology suggests that early maternal inflammation may produce abnormal neurodevelopment leading to schizophrenia in the offspring. There is increasing evidence that neuroinflammation and in particular the cytokine Interleukin 1-beta (IL-1β) may be altered in adults with schizophrenia. IL-1β mRNA and protein levels have been shown to be significantly increased in serum, plasma, cerebrospinal fluid and brain tissue in chronically ill adults with schizophrenia and in first episode psychosis. Further support comes from genetic studies in which allelic variation in the IL-1B gene has been associated with a diagnosis of schizophrenia and IL-1B risk alleles have been associated with abnormal prefrontal cortex activity and reduced prefrontal gray matter in schizophrenia. In rodents, dam exposure to Il-β and TNFα reduced dendrites and dendritic length in pups. Stress can increase IL-1β in the hippocampus and IL-1β can inhibit adult hippocampal neurogenesis which can be reversed by blockade of IL-1β. Peripheral and central IL-1β administration elicits anhedonia and deficits in social interaction and memory, which are similar to deficits found in schizophrenia. IL-1β is known as a master regulator of immune system activity. Inhibition of excessive immune response is possible by interrupting the cascade of cytokine responses which can be achieved by administering canakinumab: a human anti-interleukin 1β monoclonal antibody that interferes with the bioactivity of IL-1β. However, the extent to which IL-1β blockade by canakinumab can reduce psychotic symptoms, improve cognition and restore brain volume and activity in schizophrenia is unknown.

We will test the following hypotheses:

1) Administration of canakinumab will produce reduction in symptoms in people with schizophrenia or schizoaffective disorder who have increased NLR greater than 2 or display an elevated IL-1β ELISA assay.

2) Administration of canakinumab will produce improvements in the cognitive domains of language in people with schizophrenia or schizoaffective disorder who have increased NLR greater than 2 or display an elevated IL-1β ELISA assay.

3) Administration of canakinumab will produce reduction in peripheral IL-1β levels in people with schizophrenia or schizoaffective disorder who have increased NLR greater than 2 or display an elevated IL-1β ELISA assay at baseline.

4) Administration of canakinumab will alter brain activity during inhibition of emotional words in people with schizophrenia or schizoaffective disorder who have an increased NLR greater than 2 or display an elevated IL-1β ELISA assay at baseline.

Our hypotheses have been formulated in part on the basis of cognitive findings from our studies showing impairment in attention, working memory, language and episodic memory in schizophrenia which are cognitive domains that are negatively influenced by increased IL-1β levels. We have shown robust reductions in the cognitive processes of language, episodic memory, working memory and attention in people with schizophrenia relative to healthy adults. These hippocampal and prefrontal cortex related cognitive processes have been shown to be influenced by IL-1β, show limited improvement with antipsychotic treatment, and fail to normalize with antipsychotics in the majority of people with schizophrenia. We have also recently shown increased cytokine levels in 38% of the brains of people with schizophrenia. This is important since together with previous animal studies showing that blockade of IL-1β can restore adult hippocampal neurogenesis that had been disrupted due to early IL-1β administration, these findings suggest that administration of canakinumab which interferes with IL-1β bioactivity will reverse cognitive deficits, restore brain volume and activity, and may reduce psychotic symptoms associated with schizophrenia in those people with schizophrenia who display elevated peripheral cytokine levels.

Field of Research (FOR) Tag:

Psychiatry

Neurosciences

Cognitive Science

Psychology and Cognitive Sciences

Clinical Sciences

Learning, Memory, Cognition and Language

Teaching & Supervision

Currently supervising:

Hons:

ILP: Chiamei May Lin

PhD: Cynthia Lee

Supervision keywords:

schizophrenia

cognition

learning

memory

decision making

problem solving

genetics

clinical pharmacology

magnetic resonance imaging

Media

LinkedIn:

http://au.linkedin.com/pub/thomas-weickert/56/68/97

Publications related to this Person

Journal articles

Lee CH; Sinclair D; O'Donnell M; Galletly C; Liu D; Weickert CS; Weickert TW, 2019, 'Transcriptional changes in the stress pathway are related to symptoms in schizophrenia and to mood in schizoaffective disorder', Schizophrenia Research, vol. 213, pp. 87 - 95, http://dx.doi.org/10.1016/j.schres.2019.06.026

Weickert CS; Lee CH; Lenroot RK; Bruggemann J; Galletly C; Liu D; Balzan R; Pillai A; Buckley P; Weickert TW, 2019, 'Increased plasma Brain-Derived Neurotrophic Factor (BDNF) levels in females with schizophrenia', Schizophrenia Research, vol. 209, pp. 212 - 217, http://dx.doi.org/10.1016/j.schres.2019.04.015

Owens SJ; Weickert TW; Purves-Tyson TD; Ji E; White C; Galletly C; Liu D; O'Donnell M; Shannon Weickert C, 2019, 'Sex-Specific Associations of Androgen Receptor CAG Trinucleotide Repeat Length and of Raloxifene Treatment with Testosterone Levels and Perceived Stress in Schizophrenia.', Mol Neuropsychiatry, vol. 5, pp. 28 - 41, http://dx.doi.org/10.1159/000495062

van Erp TGM; Walton E; Hibar DP; Schmaal L; Jiang W; Glahn DC; Pearlson GD; Yao N; Fukunaga M; Hashimoto R, 2019, 'Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?', Biological Psychiatry, vol. 85, pp. e35 - e39, http://dx.doi.org/10.1016/j.biopsych.2018.10.003

Jacomb I; Stanton C; Vasudevan R; Powell H; O'Donnell M; Lenroot R; Bruggemann J; Balzan R; Galletly C; Liu D, 2018, 'C-Reactive protein: Higher during acute psychotic episodes and related to cortical thickness in schizophrenia and healthy controls', Frontiers in Immunology, vol. 9, http://dx.doi.org/10.3389/fimmu.2018.02230

Carruthers SP; Gurvich CT; Cropley VL; Pantelis C; Bousman C; Lenroot RK; Bruggemann JM; Weickert T; Rossell SL, 2018, 'The effects of a muscarinic receptor 1 gene variant on cortical thickness and surface area in schizophrenia', Psychiatry Research - Neuroimaging, vol. 280, pp. 62 - 64, http://dx.doi.org/10.1016/j.pscychresns.2018.08.014

Hoffmann C; Van Rheenen TE; Mancuso SG; Zalesky A; Bruggemann J; Lenroot RK; Sundram S; Weickert CS; Weickert TW; Pantelis C, 2018, 'Exploring the moderating effects of dopaminergic polymorphisms and childhood adversity on brain morphology in schizophrenia-spectrum disorders', Psychiatry Research - Neuroimaging, vol. 281, pp. 61 - 68, http://dx.doi.org/10.1016/j.pscychresns.2018.09.002

Cai HQ; Catts VS; Webster MJ; Galletly C; Liu D; O’Donnell M; Weickert TW; Weickert CS, 2018, 'Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation', Molecular Psychiatry, http://dx.doi.org/10.1038/s41380-018-0235-x

van Erp TGM; Walton E; Hibar DP; Schmaal L; Jiang W; Glahn DC; Pearlson GD; Yao N; Fukunaga M; Hashimoto R, 2018, 'Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium', Biological Psychiatry, vol. 84, pp. 644 - 654, http://dx.doi.org/10.1016/j.biopsych.2018.04.023

Ruderfer DM; Ripke S; McQuillin A; Boocock J; Stahl EA; Pavlides JMW; Mullins N; Charney AW; Ori APS; Loohuis LMO, 2018, 'Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes', Cell, vol. 173, pp. 1705 - 1715.e16, http://dx.doi.org/10.1016/j.cell.2018.05.046

Kelly S; Jahanshad N; Zalesky A; Kochunov P; Agartz I; Alloza C; Andreassen OA; Arango C; Banaj N; Bouix S, 2018, 'Widespread white matter microstructural differences in schizophrenia across 4322 individuals: Results from the ENIGMA Schizophrenia DTI Working Group', Molecular Psychiatry, vol. 23, pp. 1261 - 1269, http://dx.doi.org/10.1038/mp.2017.170

Van Rheenen TE; Cropley V; Zalesky A; Bousman C; Wells R; Bruggemann J; Sundram S; Weinberg D; Lenroot RK; Pereira A, 2018, 'Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities', Schizophrenia Bulletin, vol. 44, pp. 560 - 574, http://dx.doi.org/10.1093/schbul/sbx109

Bousman CA; Cropley V; Klauser P; Hess JL; Pereira A; Idrizi R; Bruggemann J; Mostaid MS; Lenroot R; Weickert TW, 2018, 'Neuregulin-1 (NRG1) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia', Psychological Medicine, vol. 48, pp. 801 - 809, http://dx.doi.org/10.1017/S0033291717002173

Owens SJ; Murphy CE; Purves-Tyson TD; Weickert TW; Shannon Weickert C, 2018, 'Considering the role of adolescent sex steroids in schizophrenia', Journal of Neuroendocrinology, vol. 30, http://dx.doi.org/10.1111/jne.12538

Fullerton JM; Klauser P; Lenroot RK; Shaw AD; Overs B; Heath A; Cairns MJ; Atkins J; Scott R; Schofield PR, 2018, 'Differential effect of disease-associated ST8SIA2 haplotype on cerebral white matter diffusion properties in schizophrenia and healthy controls', Translational Psychiatry, vol. 8, http://dx.doi.org/10.1038/s41398-017-0052-z

Weickert TW, 2018, 'Probabilistic association learning in schizophrenia', Current Opinion in Behavioral Sciences, vol. 20, pp. 1 - 8, http://dx.doi.org/10.1016/j.cobeha.2017.08.015

Glass LJ; Sinclair D; Boerrigter D; Naude K; Fung SJ; Brown D; Catts VS; Tooney P; O'Donnell M; Lenroot R, 2017, 'Brain antibodies in the cortex and blood of people with schizophrenia and controls', Translational Psychiatry, vol. 7, http://dx.doi.org/10.1038/tp.2017.134

Weickert TW; Weickert CS, 2017, 'Raloxifene improves cognition in schizophrenia: Spurious result or valid effect?', Frontiers in Psychiatry, vol. 8, http://dx.doi.org/10.3389/fpsyt.2017.00202

Boerrigter D; Weickert TW; Lenroot R; O'Donnell M; Galletly C; Liu D; Burgess M; Cadiz R; Jacomb I; Catts VS, 2017, 'Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder', Journal of Neuroinflammation, vol. 14, http://dx.doi.org/10.1186/s12974-017-0962-y

Klauser P; Baker ST; Cropley VL; Bousman C; Fornito A; Cocchi L; Fullerton JM; Rasser P; Schall U; Henskens F, 2017, 'White Matter Disruptions in Schizophrenia Are Spatially Widespread and Topologically Converge on Brain Network Hubs', Schizophrenia bulletin, vol. 43, pp. 425 - 435, http://dx.doi.org/10.1093/schbul/sbw100

Cropley VL; Klauser P; Lenroot RK; Bruggemann J; Sundram S; Bousman C; Pereira A; Di Biase MA; Weickert TW; Weickert CS, 2017, 'Accelerated gray and white matter deterioration with age in schizophrenia', American Journal of Psychiatry, vol. 174, pp. 286 - 295, http://dx.doi.org/10.1176/appi.ajp.2016.16050610

Atkinson RJ; Fulham WR; Michie PT; Ward PB; Todd J; Stain H; Langdon R; Thienel R; Paulik G; Cooper G, 2017, 'Electrophysiological, cognitive and clinical profiles of at-risk mental state: The longitudinal minds in transition (MinT) study', PLoS ONE, vol. 12, http://dx.doi.org/10.1371/journal.pone.0171657

Weinberg D; Lenroot R; Jacomb I; Allen K; Bruggemann J; Wells R; Balzan R; Liu D; Galletly C; Catts SV, 2016, 'Cognitive subtypes of schizophrenia characterized by differential brain volumetric reductions and cognitive decline', JAMA Psychiatry, vol. 73, pp. 1251 - 1259, http://dx.doi.org/10.1001/jamapsychiatry.2016.2925

Kindler J; Weickert CS; Schofield PR; Lenroot R; Weickert TW, 2016, 'Raloxifene increases prefrontal activity during emotional inhibition in schizophrenia based on estrogen receptor genotype', European Neuropsychopharmacology, vol. 26, pp. 1930 - 1940, http://dx.doi.org/10.1016/j.euroneuro.2016.10.009

Moustafa AA; Weickert TW; Frydecka D, 2016, 'Editorial: Schizophrenia: Human and animal studies', Frontiers in Behavioral Neuroscience, vol. 10, http://dx.doi.org/10.3389/fnbeh.2016.00076

Weickert CS; Weickert TW, 2016, 'What's Hot in Schizophrenia Research?', Psychiatric Clinics of North America, vol. 39, pp. 343 - 351, http://dx.doi.org/10.1016/j.psc.2016.01.011

Ji E; Weickert CS; Lenroot R; Kindler J; Skilleter AJ; Vercammen A; White C; Gur RE; Weickert TW, 2016, 'Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia', Translational Psychiatry, vol. 6, http://dx.doi.org/10.1038/tp.2016.59

Catts VS; Lai YL; Weickert CS; Weickert TW; Catts SV, 2016, 'A quantitative review of the postmortem evidence for decreased cortical N-methyl-d-aspartate receptor expression levels in schizophrenia: How can we link molecular abnormalities to mismatch negativity', Biological Psychology, vol. 116, pp. 57 - 67, http://dx.doi.org/10.1016/j.biopsycho.2015.10.013

Weickert TW; Allen KM; Weickert CS, 2016, 'Potential role of oestrogen modulation in the treatment of neurocognitive deficits in schizophrenia', CNS Drugs, vol. 30, pp. 125 - 133, http://dx.doi.org/10.1007/s40263-016-0312-0

Weickert CS; Weickert TW, 2016, 'Hormone modulation improves cognition in schizophrenia', Neuropsychopharmacology, vol. 41, pp. 384 - 385, http://dx.doi.org/10.1038/npp.2015.269

Pillai A; Howell KR; Ahmed AO; Weinberg D; Allen KM; Bruggemann J; Lenroot R; Liu D; Galletly C; Weickert CS, 2016, 'Association of serum VEGF levels with prefrontal cortex volume in schizophrenia', Molecular Psychiatry, vol. 21, pp. 686 - 692, http://dx.doi.org/10.1038/mp.2015.96

Cohen OS; Weickert TW; Hess JL; Paish LM; McCoy SY; Rothmond DA; Galletly C; Liu D; Weinberg DD; Huang XF, 2016, 'A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples', Molecular Psychiatry, vol. 21, pp. 975 - 982, http://dx.doi.org/10.1038/mp.2015.137

Fillman SG; Weickert TW; Lenroot RK; Catts SV; Bruggemann JM; Catts VS; Weickert CS, 2016, 'Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume', Molecular Psychiatry, vol. 21, pp. 1090 - 1098, http://dx.doi.org/10.1038/mp.2015.90

Wells R; Swaminathan V; Sundram S; Weinberg D; Bruggemann J; Jacomb I; Cropley V; Lenroot R; Pereira AM; Zalesky A, 2015, 'The impact of premorbid and current intellect in schizophrenia: Cognitive, symptom, and functional outcomes', npj Schizophrenia, vol. 1, http://dx.doi.org/10.1038/npjschz.2015.43

Morris RW; Purves-Tyson TD; Weickert CS; Rothmond D; Lenroot R; Weickert TW, 2015, 'Testosterone and reward prediction-errors in healthy men and men with schizophrenia', Schizophrenia Research, vol. 168, pp. 649 - 660, http://dx.doi.org/10.1016/j.schres.2015.06.030

Weickert TW; Weinberg D; Lenroot R; Catts SV; Wells R; Vercammen A; O'Donnell M; Galletly C; Liu D; Balzan R, 2015, 'Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia', MOLECULAR PSYCHIATRY, vol. 20, pp. 685 - 694, http://dx.doi.org/10.1038/mp.2015.11

Kindler J; Weickert CS; Skilleter AJ; Catts SV; Lenroot R; Weickert TW, 2015, 'Selective Estrogen Receptor Modulation Increases Hippocampal Activity during Probabilistic Association Learning in Schizophrenia', Neuropsychopharmacology, http://dx.doi.org/10.1038/npp.2015.88

Skilleter AJ; Weickert CS; Vercammen A; Lenroot R; Weickert TW, 2015, 'Peripheral BDNF: A candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia', Psychological Medicine, vol. 45, pp. 841 - 854, http://dx.doi.org/10.1017/S0033291714001925

Ji E; Weickert CS; Lenroot R; Catts SV; Vercammen A; White C; Gur RE; Weickert TW, 2015, 'Endogenous testosterone levels are associated with neural activity in men with schizophrenia during facial emotion processing', Behavioural Brain Research, vol. 286, pp. 338 - 346, http://dx.doi.org/10.1016/j.bbr.2015.03.020

Weickert T; Terrazas A; Bigelow L; Apud JA; Egan MF; Weinberger DR, 2014, 'Perceptual category judgment deficits are related to prefrontal decision making abnormalities in schizophrenia', Frontiers in Psychiatry, vol. 4, http://dx.doi.org/10.3389/fpsyt.2013.00184

Skilleter AJ; Weickert CS; Moustafa AA; Gendy R; Chan M; Arifin N; Mitchell PB; Weickert TW, 2014, 'BDNF val66met genotype and schizotypal personality traits interact to influence probabilistic association learning', Behavioural Brain Research, vol. 274, pp. 137 - 142, http://dx.doi.org/10.1016/j.bbr.2014.07.041

Vercammen A; Weickert CS; Skilleter AJ; Lenroot R; Schofield PR; Weickert TW, 2014, 'Common polymorphisms in dopamine-related genes combine to produce a 'schizophrenia-like' prefrontal hypoactivity', Translational Psychiatry, vol. 4, http://dx.doi.org/10.1038/tp.2013.125

Vercammen A; Skilleter AJ; Lenroot R; Catts SV; Weickert CS; Weickert TW, 2013, 'Testosterone is inversely related to brain activity during emotional inhibition in schizophrenia', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0077496

Weickert CS; Fung SJ; Catts VS; Schofield PR; Allen KM; Moore LT; Newell KA; Pellen D; Huang XF; Catts SV, 2013, 'Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia', Molecular Psychiatry, vol. 18, pp. 1185 - 1192, http://dx.doi.org/10.1038/mp.2012.137

Catts VS; Fung SJ; Long LE; Joshi D; Vercammen A; Allen KM; Fillman SG; Rothmond DA; Sinclair D; Tiwari Y, 2013, 'Rethinking schizophrenia in the context of normal neurodevelopment', Frontiers in Cellular Neuroscience, http://dx.doi.org/10.3389/fncel.2013.00060

Weickert CS; Weickert TW; Pillai A; Buckley PF, 2013, 'Biomarkers in schizophrenia: A brief conceptual consideration', Disease Markers, vol. 35, pp. 3 - 9, http://dx.doi.org/10.1155/2013/510402

Moore L; Kyaw M; Vercammen A; Lenroot R; Kulkarni J; Curtis J; O'Donnell M; Carr VJ; Shannon Weickert C; Weickert TW, 2013, 'Serum testosterone levels are related to cognitive function in men with schizophrenia', Psychoneuroendocrinology, vol. 38, pp. 1717 - 1728, http://dx.doi.org/10.1016/j.psyneuen.2013.02.007

Weickert TW; Mattay VS; Das S; Bigelow LB; Apud JA; Egan MF; Weinberger DR; Goldberg TE, 2013, 'Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease', Schizophrenia Research, vol. 149, pp. 162 - 166, http://dx.doi.org/10.1016/j.schres.2013.06.028

Weickert TW; Leslie F; Rushby JA; Hodges JR; Hornberger M, 2013, 'Probabilistic association learning in frontotemporal dementia and schizophrenia', Cortex, vol. 49, pp. 101 - 106, http://dx.doi.org/10.1016/j.cortex.2011.09.011

Dalton MA; Weickert TW; Hodges JR; Piguet O; Hornberger M, 2013, 'Impaired acquisition rates of probabilistic associative learning in frontotemporal dementia is associated with fronto-striatal atrophy', NeuroImage: Clinical, vol. 2, pp. 56 - 62, http://dx.doi.org/10.1016/j.nicl.2012.11.001

Morris R; Griffiths O; Le Pelley ME; Weickert TW, 2013, 'Attention to irrelevant cues is related to positive symptoms in schizophrenia', Schizophrenia Bulletin, vol. 39, pp. 575 - 582, http://dx.doi.org/10.1093/schbul/sbr192

Weickert TW, 2012, 'Reply to: Implicit memory in schizophrenia: The problem that will not go away', Biological Psychiatry, vol. 71, http://dx.doi.org/10.1016/j.biopsych.2011.07.037

Morris RW; Vercammen A; Lenroot R; Moore L; Langton JM; Short B; Kulkarni J; Curtis J; O'Donnell M; Weickert CS, 2012, 'Disambiguating ventral striatum fMRI-related bold signal during reward prediction in schizophrenia', Molecular Psychiatry, vol. 17, pp. 280 - 289, http://dx.doi.org/10.1038/mp.2011.75

Vercammen A; Morris R; Green MJ; Lenroot R; Kulkarni J; Carr VJ; Weickert CS; Weickert TW, 2012, 'Reduced neural activity of the prefrontal cognitive control circuitry during response inhibition to negative words in people with schizophrenia', Journal of Psychiatry and Neuroscience, vol. 37, pp. 379 - 388, http://dx.doi.org/10.1503/jpn.110088

Rushby JA; Vercammen A; Loo C; Short B; Weickert CS; Weickert TW, 2011, 'Frontal and parietal contributions to probabilistic association learning', Cerebral Cortex, vol. 21, pp. 1879 - 1888, http://dx.doi.org/10.1093/cercor/bhq255

Vercammen A; Rushby JA; Loo C; Short B; Weickert CS; Weickert TW, 2011, 'Transcranial direct current stimulation influences probabilistic association learning in schizophrenia', Schizophrenia Research, vol. 131, pp. 198 - 205, http://dx.doi.org/10.1016/j.schres.2011.06.021

Walenski M; Weickert TW; Maloof CJ; Ullman MT, 2010, 'Grammatical processing in schizophrenia: Evidence from morphology', Neuropsychologia, vol. 48, pp. 262 - 269, http://dx.doi.org/10.1016/j.neuropsychologia.2009.09.012

Weickert TW; Goldberg TE; Egan MF; Apud JA; Meeter M; Myers CE; Gluck MA; Weinberger DR, 2010, 'Relative Risk of Probabilistic Category Learning Deficits in Patients with Schizophrenia and Their Siblings', Biological Psychiatry, vol. 67, pp. 948 - 955, http://dx.doi.org/10.1016/j.biopsych.2009.12.027

Weickert TW; Goldberg TE; Callicott JH; Chen Q; Apud JA; Das S; Zoltick BJ; Egan MF; Meeter M; Myers C, 2009, 'Neural correlates of probabilistic category learning in patients with schizophrenia', Journal of Neuroscience, vol. 29, pp. 1244 - 1254, http://dx.doi.org/10.1523/JNEUROSCI.4341-08.2009

Jazbec S; Pantelis C; Robbins T; Weickert T; Weinberger DR; Goldberg TE, 2007, 'Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: Impact of distractors', Schizophrenia Research, vol. 89, pp. 339 - 349, http://dx.doi.org/10.1016/j.schres.2006.08.014

Blasi G; Goldberg TE; Weickert T; Das S; Kohn P; Zoltick B; Bertolino A; Callicott JH; Weinberger DR; Mattay VS, 2006, 'Brain regions underlying response inhibition and interference monitoring and suppression', European Journal of Neuroscience, vol. 23, pp. 1658 - 1664, http://dx.doi.org/10.1111/j.1460-9568.2006.04680.x

Roebuck-Spencer TM; Yarboro C; Nowak M; Takada K; Jacobs G; Lapteva L; Weickert T; Volpe B; Diamond B; Illei G, 2006, 'Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus', Arthritis Care and Research, vol. 55, pp. 434 - 441, http://dx.doi.org/10.1002/art.21992

Lapteva L; Nowak M; Yarboro CH; Takada K; Roebuck-Spencer T; Weickert T; Bleiberg J; Rosenstein D; Pao M; Patronas N, 2006, 'Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus', Arthritis and Rheumatism, vol. 54, pp. 2505 - 2514, http://dx.doi.org/10.1002/art.22031

Oroszi G; Lapteva L; Davis E; Yarboro CH; Weickert T; Roebuck-Spencer T; Bleiberg J; Rosenstein D; Pao M; Lipsky PE, 2006, 'The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus', Annals of the Rheumatic Diseases, vol. 65, pp. 1330 - 1335, http://dx.doi.org/10.1136/ard.2006.051623

Weickert TW; Goldberg TE, 2005, 'First- and second-generation antipsychotic medication and cognitive processing in schizophrenia', Current Psychiatry Reports, vol. 7, pp. 304 - 310, http://dx.doi.org/10.1007/s11920-005-0085-5

Fera F; Weickert TW; Goldberg TE; Tessitore A; Hariri A; Das S; Lee S; Zoltick B; Meeter M; Myers CE, 2005, 'Neural mechanisms underlying probabilistic category learning in normal aging', Journal of Neuroscience, vol. 25, pp. 11340 - 11348, http://dx.doi.org/10.1523/JNEUROSCI.2736-05.2005

Elvevåg B; Fisher JE; Weickert TW; Weinberger DR; Goldberg TE, 2004, 'Lack of false recognition in schizophrenia: A consequence of poor memory?', Neuropsychologia, vol. 42, pp. 546 - 554, http://dx.doi.org/10.1016/j.neuropsychologia.2003.08.013

Weickert TW; Goldberg TE; Mishara A; Apud JA; Kolachana BS; Egan MF; Weinberger DR, 2004, 'Catechol-O-methyltransferase val ^108/158met genotype predicts working memory response to antipsychotic medications', Biological Psychiatry, vol. 56, pp. 677 - 682, http://dx.doi.org/10.1016/j.biopsych.2004.08.012

Weickert TW; Goldberg TE; Marenco S; Bigelow LB; Egan MF; Weinberger DR, 2003, 'Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: Critical examination of confounds', Neuropsychopharmacology, vol. 28, pp. 1491 - 1500, http://dx.doi.org/10.1038/sj.npp.1300216

Goldberg TE; Egan MF; Gscheidle T; Coppola R; Weickert T; Kolachana BS; Goldman D; Weinberger DR, 2003, 'Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia', Archives of General Psychiatry, vol. 60, pp. 889 - 896, http://dx.doi.org/10.1001/archpsyc.60.9.889

Elvevåg B; Weickert T; Wechsler M; Coppola R; Weinberger DR; Goldberg TE, 2002, 'An investigation of the integrity of semantic boundaries in schizophrenia', Schizophrenia Research, vol. 53, pp. 187 - 198, http://dx.doi.org/10.1016/S0920-9964(01)00202-X

Weickert TW; Terrazas A; Bigelow LB; Malley JD; Hyde T; Egan MF; Weinberger DR; Goldberg TE, 2002, 'Habit and skill learning in schizophrenia: Evidence of normal striatal processing with abnormal cortical input', Learning and Memory, vol. 9, pp. 430 - 442, http://dx.doi.org/10.1101/lm.49102

Weickert TW; Goldberg TE; Gold JM; Bigelow LB; Egan MF; Weinberger DR, 2000, 'Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect', Archives of General Psychiatry, vol. 57, pp. 907 - 913, http://dx.doi.org/10.1001/archpsyc.57.9.907

Topoff H; Weickert T; Zimmerli E, 1990, 'A comparative study of colony takeover between queens of facultative and obligatory slave-making ants (Hymenoptera: Formicidae)', Journal of Insect Behavior, vol. 3, pp. 813 - 817, http://dx.doi.org/10.1007/BF01065969

Conference Papers

Van Rheenen TE; Cropley V; Wells R; Bruggemannd J; Swaminathan V; Sundram S; Weinberg D; Jacomb I; Lenroot R; Pereira AM, 2016, 'An Investigation of Brain Structural Abnormalities in Neurocognitive Subgroups of Schizophrenia', in BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE INC, pp. 392S - 392S, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000432440805108&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Weickert T; Kindler J; Lim C; Guillemin G; Boerrigter D; Zavitsanou K; Lenroot R; Weickert CS, 2016, 'Imbalance of Kynurenine Metabolism is Induced by Proinflammatory Cytokines and Associated with Working Memory and Dorsolateral Prefrontal Cortex Volume in Schizophrenia', in BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE INC, pp. 392S - 392S, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000432440805109&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Find a Person

Quick Links

	Scholarships
	Contact Us